Heron Therapeutics, Inc. (NASDAQ:HRTX)‘s stock had its “buy” rating restated by equities research analysts at Jefferies Group LLC in a report released on Friday. They currently have a $26.00 target price on the biotechnology company’s stock. Jefferies Group LLC’s target price suggests a potential upside of 60.49% from the stock’s previous close.

A number of other analysts have also issued reports on the company. Aegis reissued a “buy” rating on shares of Heron Therapeutics in a research report on Tuesday, March 21st. Zacks Investment Research lowered Heron Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Tuesday, May 9th. Noble Financial reissued a “buy” rating on shares of Heron Therapeutics in a research report on Friday, May 12th. Cantor Fitzgerald reissued an “overweight” rating on shares of Heron Therapeutics in a research report on Monday, June 26th. Finally, Cowen and Company reissued a “buy” rating and issued a $40.00 target price on shares of Heron Therapeutics in a research report on Friday, May 26th. One research analyst has rated the stock with a sell rating and eleven have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $31.89.

Heron Therapeutics (NASDAQ HRTX) opened at 16.20 on Friday. Heron Therapeutics has a 52 week low of $12.21 and a 52 week high of $24.00. The company has a 50-day moving average price of $14.19 and a 200 day moving average price of $14.10.

Heron Therapeutics (NASDAQ:HRTX) last announced its earnings results on Wednesday, May 10th. The biotechnology company reported ($1.00) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.94) by $0.06. The business had revenue of $3.63 million during the quarter, compared to the consensus estimate of $1.96 million. Analysts anticipate that Heron Therapeutics will post ($3.73) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This story was reported by Daily Political and is owned by of Daily Political. If you are accessing this story on another domain, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this story can be viewed at https://www.dailypolitical.com/2017/07/18/heron-therapeutics-inc-hrtx-stock-rating-reaffirmed-by-jefferies-group-llc.html.

In other Heron Therapeutics news, VP Kimberly Manhard sold 21,542 shares of the business’s stock in a transaction on Monday, April 24th. The shares were sold at an average price of $15.33, for a total value of $330,238.86. Following the completion of the transaction, the vice president now owns 5,250 shares in the company, valued at $80,482.50. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 20.31% of the company’s stock.

Several institutional investors have recently bought and sold shares of HRTX. Swiss National Bank increased its position in Heron Therapeutics by 39.9% in the first quarter. Swiss National Bank now owns 72,600 shares of the biotechnology company’s stock valued at $1,089,000 after buying an additional 20,700 shares during the period. Bank of New York Mellon Corp increased its position in Heron Therapeutics by 27.1% in the first quarter. Bank of New York Mellon Corp now owns 190,771 shares of the biotechnology company’s stock valued at $2,861,000 after buying an additional 40,657 shares during the period. Falcon Point Capital LLC acquired a new position in Heron Therapeutics during the first quarter valued at approximately $501,000. Searle & CO. acquired a new position in Heron Therapeutics during the first quarter valued at approximately $353,000. Finally, Wells Fargo & Company MN increased its position in Heron Therapeutics by 78.8% in the first quarter. Wells Fargo & Company MN now owns 39,579 shares of the biotechnology company’s stock valued at $595,000 after buying an additional 17,442 shares during the period.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Analyst Recommendations for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.